Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 15/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 12/20 | 0.51 |
| ▸ | CASP6 | P55212 | 10/20 | 0.51 |
| ▸ | CASP1 | P29466 | 5/20 | 0.46 |
| ▸ | CASP9 | P55211 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78881 | 0.93 | CASP3 (0.51) | KLK7KLK5CASP3CASP8CASP6 | |
| SCHEMBL78880 | 0.93 | CASP3 (0.51) | KLK7KLK5CASP3CASP8CASP6 | |
| SCHEMBL22404667 | 0.91 | KLK7 (0.47) | KLK7KLK5CASP3CASP8CASP6 | |
| SCHEMBL22404745 | 0.90 | KLK7 (0.46) | KLK7KLK5CASP3CASP8CASP6 | |
| SCHEMBL17261859 | 0.86 | CASP3 (0.59) | CASP3CASP8CASP6 | |
| SCHEMBL20980797 | 0.85 | CASP3 (0.53) | CASP3CASP8CASP6CASP1 | |
| SCHEMBL22404792 | 0.85 | PPARA (0.52) | KLK7KLK5CASP3CASP8CASP6 | |
| SCHEMBL10073348 | 0.84 | CASP3 (0.60) | CASP3CASP8CASP6 | |
| SCHEMBL626915 | 0.84 | CASP3 (0.60) | CASP3CASP8CASP6 | |
| SCHEMBL4425707 | 0.84 | CASP3 (0.60) | CASP3CASP8CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091450-B2 | Crystal of a caspase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| EP-3766873-A1 | METHOD FOR PREPARING CASPASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20210002235-A1 | A CRYSTAL OF A CASPASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002235-A1 | A CRYSTAL OF A CASPASE INHIBITOR | CASP1, CASP7, CASP14 | KLK7 1506/4885KLK5 1410/4885CASP3 10/4885 |
| US-11091450-B2 | Crystal of a caspase inhibitor | CASP1, CASP14, CASP7 | KLK7 1501/4885KLK5 1246/4885CASP3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.